Indirubin is a potent anti-inflammatory phytochemical derived from indigo naturalis. It is also endogenously produced in the intestine and detected in the circulation in mammals. Indirubin exerts its biological functions via two xenobiotic receptor systems: aryl hydrocarbon receptor (AHR) and pregnane X receptor (PXR); however, its effects on wound healing remain elusive. To investigate whether indirubin promotes wound healing, we utilized an in vitro scratch injury assay and in vivo full-thickness mouse skin ulcer model and assessed wound closure. Indirubin significantly accelerated wound closure in both the scratch assay and the skin ulcer model. Using inhibitors of cell proliferation or migration, indirubin was found to upregulate the migratory but not the proliferative capacity of keratinocytes. Activation of AHR/PXR by indirubin was confirmed by their nuclear translocation and subsequent upregulation of CYP1A1 (AHR), or UGT1A1 mRNA (PXR) and also by luciferase reporter assay (PXR). Although both AHR and PXR were activated by indirubin, its pro-migratory capacity was canceled by PXR inhibition but not by AHR inhibition and was dependent on the JNK pathway. Moreover, activated PXR was detected in the nuclei of re-epithelialized keratinocytes in human skin ulcers. In conclusion, this study shows that the indirubin-PXR-JNK pathway promotes skin wound healing.
Results
indirubin accelerates wound closure both in vitro and in vivo. Indirubin did not show any cytotoxicity at concentrations up to 10 μM in HaCaT keratinocytes ( Supplementary Fig. S1 ). We then examined its effect on wound healing using an in vitro scratch assay. The areas of wounds were reduced significantly more rapidly upon treatment with indirubin (100 nM) than upon treatment with DMSO ( Fig. 1A) . We also assessed the effect of indigo, which is a structural isomer of indirubin. Although indigo and indirubin have similar structures, the wound-healing effect of indigo was transient and only occurred during 2 to 6 h after wounding in the scratch assay (Fig. 1B) , and was only observed at a higher concentration (10 μM) than that of indirubin (100 nM).
Since indirubin promoted wound closure in keratinocytes, we evaluated its effect in vivo using mice with full-thickness wounds on their dorsal skin. When ointment containing indirubin was applied to the wounds, it significantly promoted wound closure compared with that in vehicle (DMSO)-treated mice (Fig. 1C ).
Indirubin promotes keratinocyte migration, but not proliferation. We next aimed to elucidate how indirubin promotes wound closure. There are two ways in which this can be achieved: acceleration of cell proliferation and promotion of cell migration. As shown in Fig. 2A,B , inhibition of cell proliferation by mitomycin C (MMC) did not affect the acceleration of wound closure by indirubin. MTT assay and BrdU assay confirmed that indirubin does not promote the proliferation of keratinocytes (Fig. 2C,D) . In contrast, when the cells were treated with cytochalasin D, an inhibitor of cell migration, wound closure was markedly inhibited regardless of the presence of indirubin ( Fig. 2E) . Thus, the acceleration of wound closure by indirubin probably occurs through the promotion of cell migration.
Indirubin-induced cell migration/wound closure is independent of AHR. We next examined whether indirubin activates the AHR/CYP1A1 axis. Indirubin induced the cytoplasmic-to-nuclear translocation Scratched cells were treated with DMSO (0.1%) or indigo (1, 100, or 10,000 nM) and the relative wound areas were measured (n = 18). (C) Full-thickness wounds were created on the dorsal skin of BALB/c mice, which were then treated with Vaseline containing DMSO (1%) or indirubin (262.26 ng/g Vaseline). Representative images (left) and the relative wound areas (right) after wound creation are shown (n = 6). Scale bar = 5 mm. All data are presented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001. of AHR (Fig. 3A,B ) and upregulated CYP1A1 expression ( Fig. 3C ,D) in normal human epidermal keratinocytes (NHEKs) as well as in HaCaT keratinocyte cell line. To investigate the role of AHR in the indirubin-induced upregulation of migration/wound closure, we first inhibited AHR of keratinocytes using its specific antagonist, The wound area at 10 h post-wounding relative to that of (A) is shown. (C,D) HaCaT cells were treated with indirubin (1, 10, or 100 nM) for 24 h and were assessed for cell proliferation using (C) MTT assay or (D) BrdU incorporation assay (n = 6). (E) HaCaT cells were scratched and treated with DMSO (0.1%) or indirubin (100 nM) in the absence or presence of cytochalasin D (2 μM). Relative wound areas are shown (n = 18). All data are presented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001. μm. (C,D) NHEKs (C) or HaCaT cells (D) were treated with DMSO (0.1%) or indirubin (1, 100, or 10,000 nM) for 6 h and assessed for CYP1A1 expression (n = 6). (E) HaCaT cells were treated with DMSO (0.1%) or indirubin (100 nM) in the absence or presence of an AHR antagonist, CH223191 (0.1, 1, or 10 μM), for 6 h and assessed for CYP1A1 expression (n = 6). (F) HaCaT cells were scratched and treated with DMSO (0.1%) or indirubin (100 nM) in the absence or presence of CH223191 (10 μM). Relative wound areas are shown (n = 18) and the statistical significances between DMSO and indirubin or CH223191 and CH223191 + indirubin are indicated with purple or green asterisks, respectively. (G,H) HaCaT cells were transfected with control or AHR siRNA and knockdown efficiency was evaluated at (G) AHR mRNA and (H) AHR protein levels (n = 3). Cropped blots are displayed above the graph and full-length blots are shown in Supplementary Fig. S2 . The www.nature.com/scientificreports www.nature.com/scientificreports/ CH223191. CH223191 inhibited the indirubin-induced CYP1A1 expression ( Fig. 3E ). However, it did not inhibit the indirubin-induced wound closure ( Fig. 3F ). To confirm this, we knocked down AHR using AHR siRNA. The efficiency of AHR knockdown was 80.50 ± 0.69% at the mRNA level ( Fig. 3G ) and 77.33 ± 12.90% at the protein level (Figs. 3H, S2). In accordance with the result of CH223191 treatment, AHR knockdown by siRNA did not cancel the accelerated wound closure in the presence of indirubin (Fig. 3I ). These results indicated that indirubin promotes wound closure in an AHR-independent manner.
Indirubin-induced cell migration/wound closure is dependent on PXR. Since the effect of indirubin was independent of AHR, we next examined the involvement of PXR. As shown in Fig. 4A ,B, indirubin activated PXR and induced its cytoplasmic-to-nuclear translocation in keratinocytes. To confirm the activation of PXR by indirubin, the expression of UGT1A1, one of the downstream genes of PXR, was assessed. A well-known PXR agonist, rifampicin, was used as a positive control. UGT1A1 was significantly upregulated by indirubin in both NHEKs ( Fig. 4C ) and HaCaT cells ( Fig. 4D ). Another PXR target gene CYP3A4 was also assessed and as shown in Supplementary Fig. S3A , rifampicin slightly but significantly upregulated the CYP3A4 expression in NHEKs. Indirubin also tended to slightly increase the expression of CYP3A4, but the differences were not statistically significant at concentrations of 1 and 100 nM ( Supplementary Fig. S3A ). However, when NHEKs were scratched before indirubin treatment, the CYP3A4 expression was significantly upregulated compared with that of DMSOor indirubin-treated unscratched cells or DMSO-treated scratched cells ( Supplementary Fig. S3B ), implying that indirubin and scratching synergistically activate PXR. In the scratch assay, indirubin (100 nM) accelerated the wound closure in NHEKs similarly to that in HaCaT cells ( Supplementary Fig. S4 ). We further confirmed the activation of PXR by indirubin using luciferase reporter assay. As shown in Fig. 4E , indirubin (100 nM)-treatment induced significant activation of PXR compared to that of DMSO-treated control condition (1.88 ± 0.14-fold increase compared to control), confirming the activation of PXR by indirubin in our assay system. We next investigated the effect of PXR inhibition on the indirubin-induced wound closure. A PXR specific antagonist SPA70 was used and it inhibited the indirubin-induced UGT1A1 expression ( Fig. 4F ). When the scratched cells were treated with both SAP70 and indirubin, indirubin-induced wound closure was completely inhibited (Fig. 4G ). To confirm this, we knocked down PXR using PXR siRNA. The efficiency of PXR knockdown was 67.83 ± 2.75% at the mRNA level ( Fig. 4H ) and 52.18 ± 8.55% at the protein level (Figs. 4I, S5). Unlike AHR knockdown, PXR knockdown entirely abrogated the indirubin-induced promotion of wound closure ( Fig. 4J ), implying that indirubin promotes wound closure in a PXR-dependent manner.
Indirubin promotes phosphorylation of JNK and wound closure through PXR. To obtain further insight into the mechanisms underlying the indirubin-promoted wound closure, the phosphorylation of cell migration-related signaling molecules was evaluated. Among the molecules tested, only the phosphorylation of JNK was significantly increased at 5.83 ± 1.32-fold in indirubin-and scratch-cotreated cells compared with that in DMSO-treated, unscratched cells (Figs. 5A, S6). Single treatment with indirubin or scratching tended to increase the phosphorylation of JNK (3.16 ± 1.74-fold and 1.92 ± 1.47-fold, respectively); however, the difference was not statistically significant ( Fig. 5A ). The phosphorylation of Akt and ERK was not increased by indirubin, scratch, or the combination of indirubin and scratch ( Supplementary Fig. S7 ). To assess the involvement of JNK signaling in the indirubin-induced wound closure, JNK was inhibited with an inhibitor specific for it, SP600125. In the presence of SP600125, the phosphorylation of JNK and its downstream c-jun was significantly prevented irrespective of the presence of indirubin in the scratched keratinocytes (Figs. 5B, S8). In line with these results, the indirubin-induced acceleration of wound closure was canceled in the presence of SP600125 ( Fig. 5C ), indicating that indirubin promotes cell migration and wound closure through the activation of JNK signaling in the scratched condition.
To elucidate the involvement of PXR in indirubin-induced JNK activation, PXR was knocked down with siRNA and the phosphorylation of JNK was assessed by western blotting. As shown in Fig. 5D ,E, PXR was downregulated by siRNA transfection confirmed by western blotting (knockdown efficiency 75.03 ± 8.14%) and the knockdown of PXR significantly inhibited the JNK phosphorylation induced by indirubin and scratch (Figs. 5D,E, and S9). Taking these findings together, it is proposed that indirubin-induced promotion of keratinocyte migration and wound healing is mediated via the PXR-JNK axis.
PXR is expressed in keratinocytes of human skin ulcer. Finally, we assessed the immunohistological localization of PXR in human skin ulcers, namely, burn, postsurgical, and stasis ulcers. Regardless of the ulcer type, PXR was detected in the nuclei of keratinocytes (indicated by an arrowhead) in the re-epithelialized islands from the epithelization front to its base ( Fig. 6 ).
Discussion
Among various beneficial phytochemicals, indigo naturalis extract and its salubrious component indirubin have drawn particular attention because they have been shown to exert potent anti-inflammatory effects in mouse models of inflammatory epithelial disorders, such as psoriasis and ulcerative colitis 7, 14, 25, 26 . In these mouse models, indirubin inhibits the proliferation and accelerates the differentiation of keratinocytes 7 and induces Foxp3-expressing samples derive from the same experiment and that blots were processed in parallel. (I) The siRNA-transfected cells were scratched and treated with DMSO (0.1%) or indirubin (100 nM). Relative wound areas are shown (n = 12) and the statistical significances between DMSO and indirubin in control siRNA transfected cells or AHR siRNA transfected cells are indicated with purple or green asterisks, respectively. Data are presented as mean ± SD (C-G,I) or SEM (H). *P < 0.05, **P < 0.01, and ***P < 0.001. www.nature.com/scientificreports www.nature.com/scientificreports/ regulatory T cells 26 . These diverse protective and anti-inflammatory effects of indirubin are believed to be mediated by the xenobiotic chemical receptor and transcription factor AHR 14 . The binding of ligands activates AHR, further accelerates epidermal terminal differentiation, and protects skin barrier function 27, 28 . AHR activation also contributes to the maintenance of intestinal barrier integrity 29 and, consistent with this, experimental colitis is much severer in Ahr-deficient mice than in their wild-type counterparts 30 . Additionally, AHR activation preferentially promotes regulatory T cells in the gut, which is protective against T-cell-mediated colitis 31 .
In this study, we demonstrated that indirubin facilitated keratinocyte migration in vitro and accelerated wound closure in vivo. Indirubin activated AHR and induced its cytoplasmic-to-nuclear translocation with subsequent CYP1A1 upregulation. However, the indirubin-induced migratory capacity of keratinocytes was independent of AHR since the effect of indirubin was not canceled by the knockdown of AHR or by the administration of an AHR-specific inhibitor. As a previous study indicated the possibility that indirubin activates another xenobiotic chemical receptor, PXR 17 , we next examined whether indirubin activates PXR in our assay system. Similar to its effects on AHR, indirubin activated PXR and induced its cytoplasmic-to-nuclear translocation. Using luciferase reporter assay, PXR activation by indirubin (100 nM) was further confirmed. In general, the activation of PXR upregulates the expression of the downstream genes, such as UGT1A1 23, 24 and CYP3A4 17, 32, 33 . The expression of UGT1A1 was significantly induced by indirubin and it was impaired by treatment with PXR antagonist SPA70, indicating that indirubin does activate PXR and induce its downstream gene UGT1A1 in keratinocytes. On the other hand, although CYP3A4 is one of the major target gene of PXR, keratinocytes are known to be poor producers of this xenobiotic-catabolizing enzyme [34] [35] [36] . As expected, the indirubin-induced PXR activation did not upregulate CYP3A4 expression in non-scratched keratinocytes. However, notably, indirubin significantly augmented CYP3A4 expression when the keratinocytes were scratched, indicating that indirubin and scratch synergistically activate PXR. In accordance with the activation of the PXR by indirubin and scratching, the transfection of PXR siRNA or inhibition of PXR by SPA70 significantly abrogated the indirubin-induced keratinocyte migration in the scratch assay. In a previous study using PXR-overexpressing human hepatocellular carcinoma HepG2 cells, it was proposed that PXR activation induces morphological change and migration of the cells 33 . Another study using HepG2 cells also indicated that PXR promotes the migration of these cells 37 . Noteworthy, wound healing effect of indirubin was observed at 100 nM but not at higher (10,000 nM) concentration. As far as we know, it is reported that the higher concentration i.e. at μM level of indirubin or its derivatives inhibits the invasion and migration of tumor-derived cells in vitro 38, 39 . Therefore we assume that higher concentration of indirubin negatively affects wound healing (so called high dose inhibition) and 100 nM was the optimum concentration in our experimental condition in keratinocytes. Taking these findings together, it is suggested that indirubin facilitates keratinocyte migration and wound healing via PXR activation, but not AHR signal.
To the best of our knowledge, the present study is the first to show the PXR-mediated acceleration of cutaneous wound healing by indirubin. Although the other PXR agonist rifampicin reportedly accelerates wound closure in intestinal epithelia 18 , it did not promote the wound closure in keratinocytes ( Supplementary Fig. S10 ). Thus, it seems that the acceleration of wound healing through PXR is specific to the activation with indirubin in keratinocytes. This fact raises the possibility of the involvement of additional factor in indirubin-induced wound healing of keratinocytes and it will be addressed in the future study. In addition to nutritional uptake from herbs and vegetables, indirubin is also biosynthesized from tryptophan by commensal microbiota such as Escherichia coli in the intestine and Malassezia yeast in the skin 15, 40, 41 . Evidence has suggested that the intestinal indirubin is absorbed into the blood, binds to serum albumin, circulates throughout the body, and is excreted into the urine 10, 42, 43 . This circulating indirubin exerts the biological function of activating the AHR pathway, among other potential functions 10 . Although indirubin is a dual agonist for AHR and PXR, our results clearly revealed that the PXR activation is crucial for wound closure, rather than that of AHR. In accordance with this, nuclear PXR was clearly observed in the re-epithelializing keratinocytes comprising the epithelization islands of human ulcers.
JNK signaling plays a pivotal role in epithelial wound healing by facilitating the migration and proliferation of keratinocytes 44, 45 . JNK is also known to promote the migration of HaCaT keratinocytes through activation of the PI3K/AKT and JNK pathways 46 . In the present scratch model, indirubin induced the phosphorylation of JNK and the JNK inhibitor SP600125 abrogated the indirubin-induced acceleration of wound closure. Notably, PXR-mediated CYP3A4 upregulation is also reported to be JNK-dependent 47 , suggesting the importance of the PXR-JNK axis in the process of wound closure. In conclusion, indirubin is a potential endogenous intestinal chemical that is beneficial to the skin by facilitating cutaneous wound closure via PXR activation.
Methods
Reagents and antibodies. Indirubin (purity more than 98%, Sigma-Aldrich, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and added to culture medium at final concentrations ranging from 1 nM to 10 μM. The AHR antagonist CH223191 (Merck, Darmstadt, Germany), the PXR antagonist SPA70 (Axon Medchem, Groningen, The Netherlands) the PXR agonist rifampicin (Sigma-Aldrich), the JNK inhibitor SP600125 (Abcam, Cambridge, UK), and the inhibitor of actin polymerization cytochalashin D (Sigma-Aldrich) were dissolved in DMSO and added to culture medium at final concentrations of 10, 10, 10, 40, and 2 μM, indicated with purple asterisks. (H,I) HaCaT cells were transfected with control or PXR siRNA and knockdown efficiency was evaluated by measuring (H) PXR mRNA and (I) PXR protein (n = 3). Cropped blots are displayed above the graph and full-length blots are shown in Supplementary Fig. S5 . The samples derive from the same experiment and that blots were processed in parallel. (J) The siRNA-transfected cells were scratched and treated with DMSO (0.1%) or indirubin (100 nM). Relative wound areas are shown (n = 12) and the statistical significances between DMSO and indirubin in control siRNA transfected cells are indicated with purple asterisks. Data are presented as mean ± SD (C-H, J) or SEM (I). *P < 0.05, **P < 0.01, and ***P < 0.001.
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(2019) 9:18174 | https://doi.org/10.1038/s41598-019-54754-2 www.nature.com/scientificreports www.nature.com/scientificreports/ respectively. MMC (Roche, Basel, Switzerland) was dissolved in distilled water and used at a final concentration of 5 μg/mL. The antibodies used were as follows: rabbit anti-human β-actin antibody, rabbit anti-phosphorylated ERK1/2 (Thr202/Tyr204), rabbit anti-ERK1/2, rabbit anti-phosphorylated Akt (Ser473), rabbit anti-Akt, rabbit anti-phosphorylated JNK (Thr183/Tyr185), rabbit anti-JNK, rabbit anti-phosphorylated c-jun, and rabbit antic-jun antibody (all purchased from Cell Signaling Technology, Danvers, MA), rabbit anti-human AHR antibody (H-211) (Santa Cruz Biotechnology, Dallas, TX), mouse anti-human PXR antibody (Abcam), rabbit anti-human PXR antibody (Thermo Fisher Scientific, Waltham, MA) and HRP-conjugated anti-rabbit or anti-mouse secondary antibody (Cell Signaling Technology). For immunostaining, AlexaFluor488 ® -conjugated anti-rabbit or anti-mouse secondary antibodies (Thermo Fisher Scientific) were used.
Cell culture. HaCaT cells (Cell Lines Service, Eppelheim, Germany), an immortalized human keratinocyte cell line, were maintained in Dulbecco'S Modified Eagle's Medium (DMEM; Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich), 100 units/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific). Cells were passaged every 2 to 3 days at sub-confluence. NHEKs (Lonza, Basel, Switzerland) were maintained in KBM-Gold TM Keratinocyte Basal Medium supplemented with KGM-Gold TM Keratinocyte Growth Medium SingleQuots TM Supplements and Growth Factors (Lonza), and the medium was replaced every other day. NHEKs were passaged at sub-confluence and used for experiments.
Immunocytochemistry. Cells were seeded on an eight-well μ-Slide (ibidi GmbH, Martinsried, Germany) at a density of 1,000 cells per well and incubated for 48 h. Cells were treated with DMSO (0.1%) or indirubin (100 nM) for 3 or 6 h, and then fixed with cold acetone, air-dried, and treated with 5% bovine serum albumin (Sigma-Aldrich) to block the non-specific binding of antibodies. After washing with Dulbecco's PBS (DPBS), fixed cells were incubated with primary antibodies at 4 °C overnight and further treated with AlexaFluor488 ® -conjugated secondary antibodies. Cells were then covered with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA) and observed by EVOS ® FL fluorescent microscopy (Thermo Fisher Scientific).
Immunohistochemistry. Skin ulcer tissue samples were obtained from three patients (burn ulcer, postsurgical ulcer, and stasis ulcer). Informed consent was obtained from each patient. Paraffin-embedded tissues were sectioned at a thickness of 3 μm and stained for PXR using Histofine Simple Stain Max-PO (Multi) (Nichirei Biosciences Inc., Tokyo, Japan) and the automated staining device Histostainer (Nichirei Biosciences Inc.). Hematoxylin was used for the counterstaining of nuclei. Images were captured using a virtual slide system and OlyVIA software (Olympus, Tokyo, Japan). This study was approved by the Institutional Ethics Committee of Kyushu University Hospital (Approval ID: 30-363), and conducted in accordance with the Declaration of Helsinki. Written informed consent was received from the patients prior to their inclusion in the study. Scratch assay. Cells were seeded at a density of 2 × 10 4 cells per well of a 96-well ImageLock tissue culture microplate (Essen Bioscience, Ann Arbor, MI) pre-coated with type I collagen (Nitta Gelatin Inc., Osaka, Japan). At full confluence, cell monolayers were scratched with a wound-maker (Essen Bioscience) and the scratched cells were incubated with DMSO (0.1%), indirubin (1, 10, 100, or 10,000 nM), or various inhibitors in DMEM supplemented with 10% FBS. The wound area of each well was automatically imaged every 2 h in a CO 2 incubator. The wound area relative to that at 0 h was measured using IncuCyte software (Essen Bioscience).
Cell proliferation assay. The MTT assay (Trevigen, Gaithersburg, MD) and BrdU incorporation assay (Roche) were performed in accordance with the manufacturers' instructions. For both assays, HaCaT cells were seeded in 96-well plates at a density of 5,000 cells per well and incubated for 24 h. Cells were then treated with DMSO (0.1%) or indirubin (1, 10, or 100 nM) for 24 h. For the BrdU assay, BrdU was applied in the final 2 h of indirubin treatment. The reaction products were quantified using a microplate reader (Bio-Rad Laboratories Inc., Hercules, CA) by measuring the absorbance at 570 nm for the MTT assay, or at 450 nm (reference wavelength 655 nm) for the BrdU incorporation assay.
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Total RNA was
extracted from the cells using RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions, converted to cDNA using PrimeScript RT Reagent Kit (TaKaRa Bio Inc., Kusatsu, Japan), and then applied for qPCR with SYBRGreen Premix Ex Taq (TaKaRa Bio Inc.). Reaction cycles were as follows: 95 °C for 30 s and then 40 cycles of 95 °C for 5 s and 60 °C for 20 s. The expression of each gene was normalized to the cycle threshold of β-actin (ACTB). Primers used for PCR are listed in Table 1 . siRNA transfection. Negative control siRNA, AHR siRNA (s1200), and PXR siRNA (s16911) (all purchased from Invitrogen, Carlsbad, CA) were each transfected into HaCaT cells using HiPerFect Transfection Reagent (Qiagen) or Lipofectamine RNAiMAX (Themo Fisher Scientific), in accordance with the manufacturers' instructions. Cells were mixed with siRNA, incubated for 48 h, and used for scratch assay or western blotting. The knockdown efficiency was assessed by qRT-PCR and western blotting. are displayed and full-length blots are shown in Supplementary Fig. S9 . The samples derive from the same experiment and that blots were processed in parallel for (A,B,D), respectively. Data are presented as mean ± SD (C) or SEM (A,B,E). *P < 0.05, **P < 0.01, and ***P < 0.001.
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(2019) 9:18174 | https://doi.org/10.1038/s41598-019-54754-2 www.nature.com/scientificreports www.nature.com/scientificreports/ Western blotting. HaCaT cells were seeded at a density of 3 × 10 5 cells per well in six-well plates. At full confluence, cell monolayers were scratched by a blue pipette tip and treated with DMSO (0.1%) or indirubin (100 nM) for 6 h. Protein lysates of the cells were extracted with lysis buffer (25 mM HEPES, 10 mM Na 4 P 2 O 7 •10H 2 O, 100 mM NaF, 5 mM EDTA, 2 mM Na 3 VO 4 , 1% Triton X-100) and analysed by SDS-PAGE on Bolt TM 4-12% Bis-Tris Plus Gels (Invitrogen). Proteins were then transferred to PVDF membranes (Millipore), probed with specific primary antibodies, and further treated with HRP-conjugated secondary antibodies. Immunological bands were then visualized with SuperSignal West Pico Chemiluminescence Substrate (Thermo Fisher Scientific) and imaged using the ChemiDoc TM XRS Plus System (Bio-Rad Laboratories Inc.). Signal of blots were analysed with Image Lab software (Bio-Rad Laboratories Inc.).
Luciferase reporter assay.
Luciferase reporter assay to evaluate PXR activation by indirubin was performed using Human pregnane X receptor activation assay system following the manufacturer's instructions (Puracyp Inc., Carlsbad, CA). Briefly, cells were seeded into 96-well plate and incubated overnight at 37 °C in 5%
Gene Symbol Sequence
ACTB Sense 5′-ATTGCCGACAGGATGCAGA-3′
Anti-sense 5′-GAGTACTTGCGCTCAGGAGGA-3′
AHR Sense 5′-CAAATCCTTCCAAGCGGCATA-3′
Anti-sense 5′-CGCTGAGCCTAAGAACTGAAAG-3′
CYP1A1
Sense 5′-TAGACACTGATCTGGCTGCAG-3′
Anti-sense 5′-GGGAAGGCTCCATCAGCATC-3′
CYP3A4
Sense 5′-GAAACACAGATCCCCCTGAAA-3′
Anti-sense 5′-ACTTACGGTGCCATCCCTTG-3′ PXR Sense 5′-CCCAGCCTGCTCATAGGTTC-3′
Anti-sense 5′-GGCGTAGCAAAGGGGTGTA-3′
UGT1A1
Sense 5′-CCTTGCCTCAGAATTCCTTC-3′
Anti-sense 5′-ATTGATCCCAAAGAGAAAACCAC-3′ Table 1 . Primer sequences for qRT-PCR. 
